Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Journal of Clinical Pharmacology
|
July 16, 2009
Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis
C Steven Ernest, Michael A Heathman, Rebecca E Wrishko
Pharmaceutical Research
|
March 12, 2010
Methodological comparison of in vitro binding parameter estimation: sequential vs. simultaneous non-linear regression
C Steven Ernest, Andrew C Hooker, Mats O Karlsson
The Journal of Pharmacology and Experimental Therapeutics
|
November 4, 2004
Mechanism-based inactivation of CYP3A by HIV protease inhibitors
C Steven Ernest, Stephen D Hall, David R Jones
Journal of Pharmacokinetics and Pharmacodynamics
|
August 15, 2013
Simultaneous optimal experimental design for in vitro binding parameter estimation
C Steven Ernest, Mats O Karlsson, Andrew C Hooker
Journal of Pharmacokinetics and Pharmacodynamics
|
October 14, 2014
Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
C Steven Ernest, Joakim Nyberg, Mats O Karlsson, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
March 15, 2022
PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
C Steven Ernest, Jenny Y Chien, Dipak R Patel, et al.
Clinical Pharmacokinetics
|
November 10, 2025
A Population Pharmacokinetic and Exposure-Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis
Rodney L Decker, C Steven Ernest, David B Radtke, et al.
Journal of Clinical Pharmacology
|
November 5, 2002
Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
Donna J Belle, C Steven Ernest, John-Michael Sauer, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
March 27, 2024
A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis
Rodney L Decker, C Steven Ernest, David B Radtke, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
November 22, 2008
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
C Steven Ernest, David S Small, Shashank Rohatagi, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Journal of Clinical Pharmacology
|
July 16, 2009
Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis
C Steven Ernest, Michael A Heathman, Rebecca E Wrishko
Pharmaceutical Research
|
March 12, 2010
Methodological comparison of in vitro binding parameter estimation: sequential vs. simultaneous non-linear regression
C Steven Ernest, Andrew C Hooker, Mats O Karlsson
The Journal of Pharmacology and Experimental Therapeutics
|
November 4, 2004
Mechanism-based inactivation of CYP3A by HIV protease inhibitors
C Steven Ernest, Stephen D Hall, David R Jones
Journal of Pharmacokinetics and Pharmacodynamics
|
August 15, 2013
Simultaneous optimal experimental design for in vitro binding parameter estimation
C Steven Ernest, Mats O Karlsson, Andrew C Hooker
Journal of Pharmacokinetics and Pharmacodynamics
|
October 14, 2014
Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
C Steven Ernest, Joakim Nyberg, Mats O Karlsson, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
March 15, 2022
PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together
C Steven Ernest, Jenny Y Chien, Dipak R Patel, et al.
Clinical Pharmacokinetics
|
November 10, 2025
A Population Pharmacokinetic and Exposure-Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis
Rodney L Decker, C Steven Ernest, David B Radtke, et al.
Journal of Clinical Pharmacology
|
November 5, 2002
Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics
Donna J Belle, C Steven Ernest, John-Michael Sauer, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
March 27, 2024
A population pharmacokinetic model using allometric scaling for baricitinib in patients with juvenile idiopathic arthritis
Rodney L Decker, C Steven Ernest, David B Radtke, et al.
Journal of Pharmacokinetics and Pharmacodynamics
|
November 22, 2008
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
C Steven Ernest, David S Small, Shashank Rohatagi, et al.
Page
of 3